All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
What is early data telling us about the potential of oncolytic virotherapy for patients with TCL?
Featured:
Joselle CookDuring the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Joselle Cook, Mayo Clinic, Rochester, US. We asked, What is early data telling us about the potential of oncolytic virotherapy for patients with T-cell lymphoma (TCL)?
What is early data telling us about the potential of oncolytic virotherapy for patients with TCL?
Vesicular stomatitis virus (VSV) has been engineered to encode interferon-beta (IFNβ) and sodium iodide symporter (NIS) to produce the virotherapy VSV-IFNβ-NIS. Cook summarizes results from a phase I trial investigating safety and efficacy with dose-escalation of VSV-IFNβ-NIS among patients with TCL.